BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

Please provide your email address to receive an email when new articles are posted on . From weeks 17 to 62 of treatment, azithromycin was highly effective in children with bronchiectasis. Birth ...

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...

DelveInsight’s “Non-cystic Fibrosis Bronchiectasis (NCFBE) Pipeline Insight” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Non-cystic Fibrosis Bronchiectasis ...

Bronchiectasis may affect anyone of any age, but most commonly the middle-aged segment. Unfortunately, the damage done to the lungs by bronchiectasis is permanent. The bronchi are small tubes in the ...